NovaBridge Biosciences (NBP) Income Statement
NBP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNBP revenue and net income
NBP profit margins
NBP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NBP quarterly EPS vs estimates
NovaBridge Biosciences beat the analyst EPS estimate in 4 of the last 8 quarters.
NBP income statement
| 2025 | 2024 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.54B | $30.0M | $53.8M | $11.3M |
| Cost of revenue | $858,263 | — | $0 | $0 | $0 | −$290,652 |
| Gross profit | −$858,263 | — | $1.54B | $30.0M | $53.8M | $11.6M |
| Research & development | $9.0M | $158.9M | $984.7M | $840.4M | $426.0M | $267.1M |
| Sales, general & admin | $4.5M | $216.5M | $402.4M | $654.6M | $66.4M | $25.4M |
| Total operating expenses | $13.5M | $375.4M | $1.39B | $1.49B | $492.4M | $292.5M |
| Operating income | −$13.5M | −$375.4M | $155.6M | −$1.46B | −$455.7M | −$273.9M |
| Interest income | $7.6M | $7.5M | — | — | — | — |
| Interest expense | — | — | $146,480 | $427,481 | $1.7M | $864,338 |
| Income before taxes | −$12.6M | −$362.7M | $483.1M | −$1.45B | −$416.8M | −$290.7M |
| Income taxes | — | — | $12.2M | — | $1.7M | — |
| Net income | −$6.6M | −$162.3M | $470.9M | −$1.45B | −$402.8M | −$298.2M |
| EBITDA | −$12.6M | −$368.3M | $168.3M | −$197.3M | −$431.9M | −$279.3M |
| EPS (diluted) | −$0.48 | −$1.42 | $1.42 | −$24.89 | −$6.92 | — |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 102.6% |
| Operating margin | — | — | 10.1% | −4,883.2% | −847.4% | −2,431.2% |
| Net margin | — | — | 30.5% | −4,826.8% | −749.0% | −2,647.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $238.0M | $0 | $0 | $0 | $0 | $71.6M | $1.1M | $0 | $9.8M |
| Cost of revenue | — | $216,942 | — | $216,289 | — | — | — | — | $0 | $20.3M | $30.5M | $0 |
| Gross profit | — | −$216,942 | — | $238.0M | — | — | — | — | $71.6M | −$19.2M | −$30.5M | $9.8M |
| Research & development | $7.1M | $7.2M | $55.7M | $3.2M | $3.3M | $777,000 | $6.0M | $4.5M | $109.4M | $39.0M | $45.4M | $223.2M |
| Sales, general & admin | $13.2M | $13.2M | $17.2M | $5.8M | $3.8M | $4.5M | $7.3M | $7.9M | $86.7M | $51.7M | $104.0M | $122.5M |
| Total operating expenses | $20.3M | $20.4M | $72.9M | $9.0M | $7.1M | $5.3M | $13.4M | $12.4M | $196.2M | $90.6M | $149.4M | $345.7M |
| Operating income | −$20.3M | −$20.4M | −$72.9M | −$9.0M | −$7.1M | −$5.3M | −$13.4M | −$12.4M | −$124.6M | −$90.6M | −$179.9M | −$335.9M |
| Interest income | — | — | $1.8M | $2.1M | $1.8M | $1.9M | $2.2M | $2.4M | $2.1M | — | — | — |
| Income before taxes | −$18.9M | −$18.9M | −$72.9M | −$6.8M | −$5.5M | −$3.1M | −$10.8M | −$20.5M | −$58.4M | −$70.0M | −$392.7M | −$386.4M |
| Income taxes | — | — | — | −$384.4M | — | −$84.2M | — | — | $6.6M | — | −$149.1M | — |
| Net income | −$18.9M | −$18.9M | −$30.8M | −$6.8M | −$5.5M | −$3.1M | −$9.1M | −$20.5M | −$33.0M | $20.8M | −$243.6M | −$386.4M |
| EBITDA | −$18.1M | −$19.6M | −$72.7M | −$7.4M | −$7.1M | −$5.3M | −$13.2M | −$6.4M | −$118.6M | −$84.6M | −$173.5M | $323.8M |
| EPS (diluted) | −$0.07 | −$0.04 | −$0.31 | −$0.06 | −$0.07 | −$0.04 | −$0.06 | −$0.11 | $0.30 | — | — | — |
| Gross margin | — | — | — | 100.0% | — | — | — | — | 100.0% | −1,687.5% | — | 100.0% |
| Operating margin | — | — | — | −3.8% | — | — | — | — | −173.9% | −7,979.7% | — | −3,417.8% |
| Net margin | — | — | — | −2.9% | — | — | — | — | −46.1% | 1,835.2% | — | −3,931.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NBP's financial statements (latest annual report filed April 7, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NBP financial results
NovaBridge Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $6.6 million. Diluted earnings per share came to −$0.48.
See the NBP stock overview for the latest quote and news, or the NBP chart for price history and technical indicators.
NBP income statement FAQ
Does NovaBridge Biosciences have revenue?
NovaBridge Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is NovaBridge Biosciences profitable?
No. NovaBridge Biosciences reported a net loss of $6.6 million in fiscal 2025.
How much does NovaBridge Biosciences spend on research and development?
NovaBridge Biosciences spent $9.0 million on research and development in fiscal 2025.
What are NovaBridge Biosciences's earnings per share?
NovaBridge Biosciences earned $-0.48 per diluted share in fiscal 2025, compared with $-1.42 a year earlier.
When does NovaBridge Biosciences's fiscal year end?
NovaBridge Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 7, 2026.